SRR35579807
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.500
- MYC_TARGETS_V2+0.460
- IL2_STAT5_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.370
- COMPLEMENT+0.320
- E2F_TARGETS+0.300
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- PROTEIN_SECRETION-0.290
- ANGIOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.270
- TGF_BETA_SIGNALING-0.270
- NOTCH_SIGNALING-0.210
- UV_RESPONSE_DN-0.200
- HEDGEHOG_SIGNALING-0.180
- WNT_BETA_CATENIN_SIGNALING-0.130
- APICAL_JUNCTION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0C0-01A-21R-A056-07 | — | C | 0.882 |
| 2 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.869 |
| 3 | SRR975600 | — | — | 0.866 |
| 4 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.864 |
| 5 | TCGA-CQ-5327-01A-01R-1686-07 | — | — | 0.848 |
| 6 | ERR2208905 | — | — | 0.848 |
| 7 | BSR_02_0048_A10_S104 | — | C | 0.842 |
| 8 | TCGA-CV-7099-01A-41R-2016-07 | — | — | 0.840 |
| 9 | TCGA-4Z-AA7W-01A-11R-A39I-07 | — | — | 0.836 |
| 10 | BS_GJNCYABP | ATRT | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |